Search results
Beware the next generation of phishing attacks
If phishing scams are supposed to trick people, why do so many of them still feel clumsy?
For years, the answer was simple: Most scams were mass-produced.
Cambridge Index advances 1.8%
The Cambridge Index climbed 472.1 points or 1.8% to close at 27,215.7, as six out of the top ten index heavyweights posted weekly gains in their share price.
Why Cambridge UK remains a global hub for antibody discovery
Cambridge UK has long been one of the world’s most important centres for life sciences, translational research and biotechnology innovation.
NGS in antibody discovery: Why sequence depth matters
Next-generation sequencing is changing how antibody discovery teams understand library performance, selection outputs and candidate diversity.
Antibody discovery and IP risk: Why freedom to operate matters earlier than you think
In antibody discovery, identifying a promising binder is only part of the challenge. For well-established targets, companies also need to consider whether the resulting sequences are novel, patentable and commercially usable.
Unlocking hard-to-drug targets with VHH antibody discovery
Many high-value therapeutic targets remain difficult to drug, particularly where targets are intracellular, conformationally complex, poorly accessible, highly conserved or embedded in membrane environments.
Nature loss brings catastrophic risks – ARU report
Food security is under threat, which could lead to economic and social instability.
Weight loss drugs boom drives pharma R&D returns, but industry could face ‘bubble’ effect
- Top global pharma companies’ return on R&D increased for third consecutive year;
- Growth is almost entirely driven by GLP-1 drugs - used to treat obesity and diabetes - and accounts for 38% of projected sales;
- Obesity drugs have displaced oncology dr
AVEVA to invest c.£30million in Cambridge Research and Development hub to support future growth
Global industrial software leader to consolidate its Cambridge teams at Science Park global HQ ahead of a 2027 opening, reinforcing its long-term commitment to the city and its Industrial Intelligence strategy.
Whitepaper: Validating synthetic VHH libraries for therapeutic discovery
Synthetic VHH libraries are becoming an increasingly important route for antibody discovery, offering a faster, more controlled alternative to traditional immunisation-based workflows.
VHH bolt-ons: Modular building blocks for smarter biologics
VHH single-domain antibodies are increasingly being used as modular building blocks in next-generation biologics.
Why antigen format matters in VHH antibody discovery
Successful antibody discovery depends not only on the discovery platform, but also on how well the target antigen is prepared, presented and controlled.
Rethinking ADC design: The role of VHHs in precision oncology
Antibody–drug conjugates have become a major platform in precision oncology, combining the targeting ability of antibodies with the potency of cytotoxic payloads.
When is a Printed Battery better than a Coin cell?
What if the biggest limitation in next-gen electronics isn’t the chip—but the battery?? As electronics continue to shrink and diversify, the limitations of traditional coin cell batteries are becoming harder to ignore.
Daniel Zeichner MP welcomes Astrazeneca’s £300 million investment as boost for Cambridge
Daniel Zeichner, MP for Cambridge, has welcomed the announcement made by the Prime Minister, Sir Keir Starmer, during Prime Minister’s Questions today that AstraZeneca will invest £300 million into the UK’s life sciences sector.
The Cambridge announces major multi-year partnership with Concrete Rose alongside new Community Fund grants
The Cambridge Building Society has announced new grants for charities supporting people with housing needs – including a new multi-year partnership with Concrete Rose Collective.
Sable&Hawkes deliver new multi-million environment development project for Luton and Dunstable NHS
Client: Bedfordshire Hospitals NHS Foundation Trust Project: New Acute Services & Multi-Ward Block
20 years of 12 Degrees: A Cambridge business story built on trust, detail and people
Est. 2006 · Celebrating 20 Years By Jen Townsend, Founder, 12 Degrees Ltd · May 2026
12 gene therapies converge on retinitis pigmentosa and a $3.4bn market by 2033
This month Gene Scope Intelligence (www.genescope-intelligence.com), a dedicated gene therapy market intelligence platform releases a brand new commercial analysis and demand forecast for new gene therapies directed at Retinitis Pigmentosa (RP).
The commercial case for electric freight is closer than you think, but three things are blocking it
A new report from operator-led logistics innovation platform TwentyForty says the UK's Plug-in Truck Grant is being absorbed by large fleets placing volume orders, shutting out smaller hauliers who make up more than half the UK truck market. The report calls on government to ring-fence at least 40% of annual grant funding for operators with fewer than 50 vehicles.
A founder’s guide to prototyping — without wasting time or money
For first-time founders, product development rarely begins with clarity.
Innovate Cambridge to recognise a new wave of companies at the Business Weekly Awards
Innovate Cambridge has announced a new award category for this year’s prestigious Business Weekly Awards, recognising a new generation of science and technology companies redefining what successful innovation looks like.
Self-Service Course or Sprint: First Job
We empower graduates fresh out of university to land their first job in competitive industries.
Recruiting is K-shaped, much like dating, with the lion share of interviews going to the minority that cracks the code.
How movement and physiotherapy can reduce stress at work
Modern workplaces often involve long hours sitting at desks, tight deadlines, and constant digital communication. These factors can significantly increase stress levels and negatively affect both physical and mental health.